Nitazoxanide versus Metronidazole for Clostridium difficileAssociated Colitis
To the Editor-Reports of increased incidence and severity of Clostridium difficile-associated colitis have stimulated interest in the search for additional treatment options for this clinical problem. Musher et al. [1] recently reported the results of a noninferiority study that compared metronidazole with nitazoxanide for the treatment of C. difficile colitis. The authors concluded that "nitazoxanide is as effective as metronidazole" (p. 425) for this infection. Scrutiny of some aspects of the study design and analysis calls this conclusion into question.
Notably, there was an unexplained exclusion of a significant number of the initially enrolled patients. The investigators compared the baseline characteristics and severity of illness in an "intent-to-treat" population; however, 32 enrolled and randomized patients were excluded before any efficacy analysis. Therefore, this was not an intent-to-treat analysis. The 110 subjects included in the primary efficacy analysis may have been very different than the initial 142 enrolled patients, and some effects of randomization were possibly lost. In addition, it is not revealed specifically what adverse events occurred among the excluded patients, and the cause of death was not revealed for any patient. The reader is told that 9.1% of the original 142 patients died, "indicating the severity of underlying disease(s) and/or the colitis" [1, p. 424] . This implies that some deaths were due to complications of C. difficileassociated colitis. This point should have been clarified. If adverse events or deaths were even peripherally related to colitis, the exclusion of these patients brings the study results into question.
There were other concerns regarding this study. (1) The investigators did not analyze the minimum number of subjects required in each group and, therefore, did not achieve adequate statistical power to reject the null hypothesis. (2) When using an active control with no placeboonly group, one should employ a doubledummy design to maintain true doubleblinding. Metronidazole and nitazoxanide do not resemble one another and have different dosing schedules. Although the randomization was blinded, it appears that the study drugs were not administered in a strictly double-blind fashion. (3) The reader is not told the proportion of subjects in each group who continued to receive the original offending antibiotic(s) that presumably led to C. difficile-associated colitis. With such a small study, one cannot rely on randomization to eliminate the effects of this potential confounder.
On the basis of in vitro susceptibility data, a hamster model of disease [2] , and the clinical trial by Musher et al. [1] , it appears that nitazoxanide does have some efficacy in treating C. difficile-associated colitis. However, one should not conclude that it is as effective as metronidazole on the basis of this study. If noninferiority to metronidazole had been shown appropriately, the significantly higher cost of nitazoxanide makes this drug difficult to recommend as an alternative treatment. The role of nitazoxanide in current clinical practice remains undefined.
Reply to Young et al.
To the Editor-We thank Young et al. [1] for their interest in our article. We believe that we can answer their queries and leave them confident in the validity of our conclusion-namely, that nitazoxanide is at least as effective as metronidazole for treatment of Clostridium difficile-associated colitis.
First and most importantly, the blinded, prospective nature of the study precluded bias. Exclusions and evaluations of adverse events or outcome were determined on the basis of predefined criteria without knowledge of treatment group assignment. No study is truly blinded if the investigators can determine the treatment group by examining the pills, and we, of course, used a "double-dummy" design. Each patient took 1 yellow tablet (nitazoxanide or a matching placebo) twice daily and 1 white tablet (metronidazole or a matching placebo) 4 times daily. The senior author (D.M.M.) preferred not to use the term "double-dummy" in the final article because it is jargon.
In our article, the text and figure 1 provided the reasons for excluding 32 patients; the reasons included death (4 patients); other adverse events, such as transfer of status to "nothing by mouth" (10 patients); dropping out (12 patients; generally because medications were not given when the patients were transferred from ward to ward); other medications for treatment of C. difficile infection ordered by residents (3 patients); and noncompliance (3 patients). The exclusions were equally distributed among the groups. Deaths specifically due to colitis did not occur. Characteristics of the remaining 110 patients, including the proportions who continued to receive the offending antibiotic(s), were similar among the 3 treatment groups (table 1) . Even if all 32 excluded patients were regarded as having experienced treatment failure in a pure intent-to-treat analysis, the response rate for nitazoxanide was 5.8% higher (95% CI, Ϫ11.2% to 23.9%) than that for metronidazole. The sample size for the primary efficacy analysis was prospectively calculated to provide 80% power to demonstrate noninferiority of nitazoxanide to metronidazole with 105 patients analyzed (35 patients per group) using a 1-sided .025 significance level, a 15% noninferiority margin, and an expected response rate of 93% for each treatment group based on previous studies of metronidazole and vancomycin [2] [3] [4] . The number was rounded up to 38 patients per group (114 total) to allow for the loss of р9 patients owing to other causes. Upon completion of the study, 110 patients were analyzed. The lower response rates observed during the study reduced the power of the statistical test. Nevertheless, nitazoxanide demonstrated noninferiority, primarily because it produced a response rate 7.1% higher than that of metronidazole. The statistical power to reject the null hypothesis becomes irrelevant, because the null hypothesis was, in fact, rejected.
Regarding the clinical application of our findings, we agree with Dr. Bartlett's editorial commentary: "On the basis of cost and experience, nitazoxanide does not appear to be justified for initial treatment, but it might be used for patients who fail to respond to metronidazole therapy, who cannot take metronidazole, or who have repeated recurrences" [5, 
Rotavirus G9 Severity Data Revisited
To the editor. Linhares et al. [1] and the accompanying editorial commentary by Kang [2] describe an association between rotavirus serotype G9 (hereafter referred to as G9) infection and severity of diarrhea among infants from Brazil, Mexico, and Venezuela in [2001] [2002] . Such a finding is important when 1100 million rotavirus infections and 440,000 deaths occur yearly among children !5 years of age [3] . G9 has emerged as the fifth most common rotavirus serotype; however, specific coverage of G9 strains is not included in 2 well-studied, currently available vaccines [4] [5] [6] .
Several issues warrant additional comment. Linhares et al. [1] used data collected from 454 infants in the placebo group of a rotavirus vaccine study [7] who met criteria for the primary efficacy analysis; these were "subjects who received 2 doses of study vaccine or placebo [and] who had no rotavirus other than vaccine strain in stool samples collected from the first dose until 2 months after the second dose" (p. 809). Because the second placebo dose was administered at a mean of 18.1 weeks, the primary efficacy analysis data only include subjects between 5-12 months of age.
Sixteen additional placebo recipients developed rotavirus infection (all due to the G1 serotype) between receipt of the first and second placebo doses; one-half of the infections were severe [7] . The primary efficacy analysis data excluded these recipients, thereby artificially elevating G9 prevalence to 29% (15 of 51; from 22% [15 of 67]). Eight of the excluded G1 episodes were severe, potentially impacting calculations and comparisons with G9.
Two recipients of placebo each experienced 2 separate episodes of rotavirus gastroenteritis: 1 patient experienced 2 G1 infections, and the other experienced a G9 infection followed by a G1 infection [7] ; however, it appears that these recipients were included in the primary efficacy analysis. Prior infection with rotavirus reduces subsequent infection severity [8] , which is also important in vaccine protection against severe disease [5] [6] [7] . Inclusion of these 2 subjects who experienced second G1 infections in the severity analysis would, therefore, decrease G1 infection severity calculations.
Data are provided regarding the age at hospitalization and not at infection [1] ; however, data suggest that G1 disease might occur earlier. If all episodes of rotavirus are considered, it is likely that G1 infections occurred earlier than G9 infections-a fact that is difficult to attribute to maternal antibodies. Another possibility, as alluded to by Kang [2] , is that a G9 epidemic occurred, as serotype data in Venezuela, Mexico, and Brazil are sparse and vary regionally [9-11]. The natural incidence of severe rotavirus gastroenteritis peaks among patients aged 9-11 months [12]; a G9 infection epidemic in 2002 would have encountered many infants in this age range. Although introduction of a new strain of rotavirus into a new population should result in disease across all age groups, as Kang argues [2] , the failure to document cases of adult disease does not provide evidence against an epidemic. Adults are rarely tested for rotavirus, and serotype data are lacking, with few exceptions [11, 13, 14] . Thus, failure to appreciate an epidemic among adults does not exclude a late G9 epidemic, which could account for excess G9 infection severity.
These important issues complicate the G9 infection severity calculations that have global implications for the development of several rotavirus vaccines (for which G9 efficacy data are limited) [5] [6] [7] . Voluntary ingestion of G1 versus G9 in a randomized, blinded trial [13], although unpalatable, is necessary to completely clarify the relationship between serotype and severity of diarrhea.
